## **PCT**

## WORLD INTELLECTUAL PROPERTY ORGANIZATION International Bureau



INTERNATIONAL APPLICATION PUB  1) International Patent Classification 7:			1) International Publication Number:	WO 00/15266
A61K 49/00	A2		3) International Publication Date:	23 March 2000 (23.03.00)
21) International Application Number: PCT/EP99/06830 22) International Filing Date: 15 September 1999 (15.09.99)		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,		
60) Priority Data: 98117598.7 16 September 1998 (19			SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS MW, SD, SL, SZ, TZ, UG, ZW). Eurasian patent (AM, AZ BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA GN, GW, ML, MR, NE, SN, TD, TG).	
<ol> <li>Applicant (for all designated States except US): GOLI BIOGLAN PHARMA GMBH [DE/DE]; Am Wass 11, D-86441 Zusmarshausen (DE).</li> </ol>		lAM berg		
72) Inventors; and 75) Inventors/Applicants (for US only): FRANK, Am Wasserberg 11, D-86441 Zusmarshau ANETTINO, Andreina [IT/IT]; Via France I-00143 Roma (IT).	usen (DE).	GI-	Published  Without international search upon receipt of that report.	report and to be republished
74) Agent: WIBBELMANN, Jobst; Wuesthoff Schweigerstrasse 2, D-81541 München (DE	& Wuest 3).	thoff,		
(54) Title: RADIO-CONTRAST AGENTS				
(57) Abstract				•
•	tereoisomer tide effects	r of a	compound with at least one chiral centre dministration, or is less chemotoxic, than	wherein said stereoisomer
(57) Abstract  An imaging or contrast agent comprising a st in stereoisomeric excess and causes fewer adverse s	tereoisomer	r of a	compound with at least one chiral centre dministration, or is less chemotoxic, than	wherein said stereoisomer
(57) Abstract  An imaging or contrast agent comprising a st in stereoisomeric excess and causes fewer adverse s	tereoisomer side effects	r of a	compound with at least one chiral centre dministration, or is less chemotoxic, than	wherein said stereoisomer
(57) Abstract  An imaging or contrast agent comprising a st in stereoisomeric excess and causes fewer adverse s	tereolsomer side effects	r of a	compound with at least one chiral centre dministration, or is less chemotoxic, than	wherein said stereoisomer
(57) Abstract  An imaging or contrast agent comprising a st in stereoisomeric excess and causes fewer adverse s	tereoisomer side effects	r of a	compound with at least one chiral centre dministration, or is less chemotoxic, than	wherein said stereoisomer
(57) Abstract  An imaging or contrast agent comprising a st in stereoisomeric excess and causes fewer adverse s	tereoisomer side effects	r of a	compound with at least one chiral centre dministration, or is less chemotoxic, than	wherein said stereoisomer
(57) Abstract  An imaging or contrast agent comprising a st in stereoisomeric excess and causes fewer adverse s	tereoisomer side effects	r of a	compound with at least one chiral centre dministration, or is less chemotoxic, than	wherein said stereoisomer
(57) Abstract  An imaging or contrast agent comprising a st in stereoisomeric excess and causes fewer adverse s	tereoisomer	r of a	compound with at least one chiral centre dministration, or is less chemotoxic, than	wherein said stereoisomer